Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Minodronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 9/20 | 0.97 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.97 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minodronic Acid SCHEMBL145238 | 0.99 | FDPS (1.00) | FDPSGGPS1GPR84BTN3A1PDE3A | |
| Minodronic Acid SCHEMBL8661646 | 0.97 | FDPS (0.97) | FDPSGGPS1GPR84BTN3A1PDE3A | |
| Minodronic Acid SCHEMBL8664061 | 0.92 | FDPS (0.83) | FDPSGGPS1GPR84BTN3A1PDE3A | |
| Minodronic Acid SCHEMBL8659642 | 0.92 | FDPS (0.83) | FDPSGGPS1GPR84BTN3A1PDE3A | |
| Minodronic Acid SCHEMBL8661643 | 0.91 | FDPS (0.85) | FDPSGGPS1GPR84BTN3A1PDE3A | |
| SCHEMBL12309035 | 0.83 | FDPS (0.73) | FDPSGGPS1GPR84NPSR1DRD4 | |
| SCHEMBL17519343 | 0.83 | FDPS (0.72) | FDPSGGPS1GPR84NPSR1DRD4 | |
| (2-Hydroxy-3-Imidazo[1,2-A]Pyridin-3-Yl-2-Phosphonopropionic Acid (Enantionmers) SCHEMBL7858749 | 0.83 | FDPS (0.72) | FDPSGGPS1GPR84NPSR1DRD4 | |
| SCHEMBL28033480 | 0.83 | FDPS (0.72) | FDPSGGPS1GPR84NPSR1DRD4 | |
| SCHEMBL17519328 | 0.81 | GGPS1 (0.69) | FDPSGGPS1GPR84NPSR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-217248314-U | Raw material mixing device is used in production of minodronic acid-hydrate | 大连韦德生化科技有限公司 | 2022-08-23 | — | — | CN | claimed |
| CN-217141180-U | Raw material processing equipment is used in production of minodronic acid monohydrate | 大连韦德生化科技有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-217058175-U | Vacuum drying device of minodronic acid monohydrate preparation | 大连韦德生化科技有限公司 | 2022-07-26 | — | — | CN | claimed |
| CN-216917619-U | Adjustable collecting device for production of minodronic acid monohydrate | 大连韦德生化科技有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114384186-A | Method for measuring content of (2E, 4E) -ethyl-4- (pyridine-2-yl imino) -2-ethyl crotonate | 王立强 | 2022-04-22 | — | — | CN | claimed |
| EP-0647649-B1 | NOVEL CRYSTAL OF MONOHYDRATE OF HETEROCYCLIC BIS(PHOSPHONIC ACID) DERIVATIVE | YAMANOUCHI PHARMA CO LTD (JP) | 1998-11-11 | — | — | EP | claimed |
| US-5480875-A | 1-HYDROXY-2-(IMIDAZO(1,2A)PYRIDIN-3-YL)ETHANE-1,1-BIS (PHOSPHONIC ACID) | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1996-01-02 | — | — | US | claimed |
| EP-0647649-A1 | NOVEL CRYSTAL OF MONOHYDRATE OF HETEROCYCLIC BIS(PHOSPHONIC ACID) DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-04-12 | — | — | EP | claimed |
| US-12427113-B2 | Cellulose composition, tablet, and orally disintegrating tablet | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-09-30 | — | — | US | disclosed |
| EP-4056637-B1 | CELLULOSE COMPOSITION AND TABLET | ASAHI CHEMICAL IND (JP) | 2025-02-12 | — | — | EP | disclosed |
| US-20240317751-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-09-26 | — | — | US | disclosed |
| CN-117794578-A | Patch and method for producing the same | 株式会社钟化 | 2024-03-29 | — | — | CN | disclosed |
| CN-112390823-B | Synthesis method of minodronic acid | 鲁南制药集团股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-116178439-A | Preparation method of minodronic acid dimer impurity | 南京海纳医药科技股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-5480875-A | 1-HYDROXY-2-(IMIDAZO(1,2A)PYRIDIN-3-YL)ETHANE-1,1-BIS (PHOSPHONIC ACID) | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| US-5480875-A | 1-HYDROXY-2-(IMIDAZO(1,2A)PYRIDIN-3-YL)ETHANE-1,1-BIS (PHOSPHONIC ACID) | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| EP-0647649-A1 | NOVEL CRYSTAL OF MONOHYDRATE OF HETEROCYCLIC BIS(PHOSPHONIC ACID) DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0647649-A1 | NOVEL CRYSTAL OF MONOHYDRATE OF HETEROCYCLIC BIS(PHOSPHONIC ACID) DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0647649-A4 | NOVEL CRYSTAL OF MONOHYDRATE OF HETEROCYCLIC BIS(PHOSPHONIC ACID) DERIVATIVE. | YAMANOUCHI PHARMA CO LTD (JP) | 1995-02-09 | — | — | EP | disclosed |
| WO-1994000462-A1 | NOVEL CRYSTAL OF MONOHYDRATE OF HETEROCYCLIC BIS(PHOSPHONIC ACID) DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317751-A1 | PURINONE DERIVATIVE HYDROCHLORIDE | BTK, P2RY1, P2RY13 | FDPS 4396/4885GGPS1 2654/4885GPR84 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.